Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

WUXI XDC CAYMAN INC.

藥明合聯生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2268)

DELAY IN DESPATCH OF CIRCULAR

Reference is made to the announcement jointly issued by Wuxi XDC Cayman Inc. (the "**Company**"), WuXi Biologics (Cayman) Inc. and BioDlink International Company Limited dated 14 January 2026 in relation to, among others, the Offers (the "**Joint Announcement**"). Unless otherwise defined, capitalised terms used herein shall have the same meanings as defined in the Joint Announcement.

As disclosed in the Joint Announcement, the making of the Offers, the acquisition of the Offer Shares pursuant to the Share Offer and the cancellation of the Share Options pursuant to the Option Offer have been approved by written shareholders' approval from WuXi Biologics, the controlling shareholder of the Company holding more than 50% of the issued share capital of the Company, pursuant to Rule 14.44 of the Listing Rules. The Company is exempted from convening a general meeting to approve the transactions contemplated under Offers as permitted under Rule 14.44 of the Listing Rules.

As disclosed in the Joint Announcement, a circular (the "**Circular**") containing, among other things, (i) further details of the Offers, the acquisition of the Offer Shares pursuant to the Share Offer and the cancellation of the Share Options pursuant to the Option Offer; and (ii) the recommendations from the directors of the Company in respect of the Offers, is expected to be despatched to the shareholders of the Company on or before 4 February 2026 for their information.

As additional time is required for the Company to prepare and finalise certain information to be included in the Circular and certain information contained in the Composite Document will be reflected in the Circular, the Company has applied to the Stock Exchange for a waiver from strict compliance with the requirements under Rule 14.41(a) of the Listing Rules (the "**Waiver**"). It is expected that the despatch date of the Circular will be postponed to a date falling on or before 13 February 2026.

On 4 February 2026, the Stock Exchange granted the Waiver to the Company on the basis that the Company would despatch the Circular to the shareholders of the Company on or before 13 February 2026. Shareholders of the Company and potential investors should note that the Waiver granted is subject to change or withdrawal by the Stock Exchange if the Company's situation changes.

By order of the Board
WuXi XDC Cayman Inc.
Dr. Jincai Li
Executive Director and Chief Executive Officer

Hong Kong, 4 February 2026

As at the date of this announcement, the board of directors of the Company comprises (i) Dr. Jincai LI, Mr. Jerry Jingwei ZHANG and Mr. Xiaojie XI as executive directors; (ii) Dr. Zhisheng CHEN, Dr. Jijie GU and Ms. Ming SHI as non-executive directors; and (iii) Dr. Ulf GRAWUNDER, Mr. Kenneth Walton HITCHNER III and Mr. Hao ZHOU as independent non-executive directors.

* *For identification purposes only*